[go: up one dir, main page]

PE20170301A1 - Medios y metodos para el tratamiento cmv - Google Patents

Medios y metodos para el tratamiento cmv

Info

Publication number
PE20170301A1
PE20170301A1 PE2016002191A PE2016002191A PE20170301A1 PE 20170301 A1 PE20170301 A1 PE 20170301A1 PE 2016002191 A PE2016002191 A PE 2016002191A PE 2016002191 A PE2016002191 A PE 2016002191A PE 20170301 A1 PE20170301 A1 PE 20170301A1
Authority
PE
Peru
Prior art keywords
cmv
methods
expression
refers
proteins
Prior art date
Application number
PE2016002191A
Other languages
English (en)
Inventor
Corinne John
Sabine Wellnitz
Christian Schaub
Original Assignee
Pfizer
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Pfizer filed Critical Pfizer
Publication of PE20170301A1 publication Critical patent/PE20170301A1/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/005—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/12—Viral antigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/12—Viral antigens
    • A61K39/245—Herpetoviridae, e.g. herpes simplex virus
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/20—Antivirals for DNA viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/20—Antivirals for DNA viruses
    • A61P31/22—Antivirals for DNA viruses for herpes viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/04—Immunostimulants
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
    • C12N15/85—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells
    • C12N15/86—Viral vectors
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N7/00—Viruses; Bacteriophages; Compositions thereof; Preparation or purification thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/545—Medicinal preparations containing antigens or antibodies characterised by the dose, timing or administration schedule
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/57—Medicinal preparations containing antigens or antibodies characterised by the type of response, e.g. Th1, Th2
    • A61K2039/572—Medicinal preparations containing antigens or antibodies characterised by the type of response, e.g. Th1, Th2 cytotoxic response
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/57—Medicinal preparations containing antigens or antibodies characterised by the type of response, e.g. Th1, Th2
    • A61K2039/575—Medicinal preparations containing antigens or antibodies characterised by the type of response, e.g. Th1, Th2 humoral response
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/70—Multivalent vaccine
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2710/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
    • C12N2710/00011—Details
    • C12N2710/14011—Baculoviridae
    • C12N2710/14041—Use of virus, viral particle or viral elements as a vector
    • C12N2710/14043—Use of virus, viral particle or viral elements as a vector viral genome or elements thereof as genetic vectore
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2710/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
    • C12N2710/00011—Details
    • C12N2710/16011—Herpesviridae
    • C12N2710/16034—Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2710/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
    • C12N2710/00011—Details
    • C12N2710/16011—Herpesviridae
    • C12N2710/16111—Cytomegalovirus, e.g. human herpesvirus 5
    • C12N2710/16134—Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2710/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
    • C12N2710/00011—Details
    • C12N2710/16011—Herpesviridae
    • C12N2710/16111—Cytomegalovirus, e.g. human herpesvirus 5
    • C12N2710/16151—Methods of production or purification of viral material

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Virology (AREA)
  • Genetics & Genomics (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Medicinal Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Microbiology (AREA)
  • Immunology (AREA)
  • Zoology (AREA)
  • Wood Science & Technology (AREA)
  • Biotechnology (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Biomedical Technology (AREA)
  • Biochemistry (AREA)
  • General Engineering & Computer Science (AREA)
  • Molecular Biology (AREA)
  • Biophysics (AREA)
  • Mycology (AREA)
  • Epidemiology (AREA)
  • Plant Pathology (AREA)
  • Physics & Mathematics (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Oncology (AREA)
  • Communicable Diseases (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Peptides Or Proteins (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)

Abstract

Se refiere a un complejo pentamerico compuesto de proteinas CMV UL128, UL130, UL131A, gH (UL75) y gL (UL115) obtenibles por el metodo que comprende en (i) co-expresion de dichas proteinas en una celula hospedera mediante el uso de baculovirus; (ii) purificar el complejo pentamerico de las celulas hospederas y/o sobrenadante de acogida obtenidos a partir de dicha co-expresion; y (iii) almacenar opcionalmente dicho complejo en una solucion tampon que comprende un agente quelante y/o estabilizante. Tambien se refiere a una composicion de vacuna que lo comprende, siendo util en el tratamiento contra el citomegalovirus (CMV)
PE2016002191A 2014-05-08 2015-05-08 Medios y metodos para el tratamiento cmv PE20170301A1 (es)

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
LU92449 2014-05-08
LU92452 2014-05-08
LU92451 2014-05-08
LU92450 2014-05-08

Publications (1)

Publication Number Publication Date
PE20170301A1 true PE20170301A1 (es) 2017-03-30

Family

ID=53180768

Family Applications (1)

Application Number Title Priority Date Filing Date
PE2016002191A PE20170301A1 (es) 2014-05-08 2015-05-08 Medios y metodos para el tratamiento cmv

Country Status (16)

Country Link
US (1) US20150322115A1 (es)
EP (1) EP3139953A1 (es)
JP (1) JP2017515503A (es)
KR (1) KR20170002560A (es)
CN (1) CN106460010A (es)
AU (1) AU2015257330A1 (es)
BR (1) BR112016025792A2 (es)
CA (1) CA2947938A1 (es)
IL (1) IL248803A0 (es)
MX (1) MX2016014660A (es)
PE (1) PE20170301A1 (es)
PH (1) PH12016502220A1 (es)
RU (1) RU2016147987A (es)
SG (1) SG11201608977UA (es)
TW (1) TW201609792A (es)
WO (1) WO2015170287A1 (es)

Families Citing this family (17)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2015048744A2 (en) 2013-09-30 2015-04-02 Moderna Therapeutics, Inc. Polynucleotides encoding immune modulating polypeptides
EP3364981A4 (en) 2015-10-22 2019-08-07 ModernaTX, Inc. VACCINE AGAINST THE HUMAN CYTOMEGALOVIRUS
CA3019588A1 (en) 2016-04-20 2017-10-26 Merck Sharp & Dohme Corp. Cmv neutralizing antigen binding proteins
AU2017345766A1 (en) 2016-10-21 2019-05-16 Modernatx, Inc. Human cytomegalovirus vaccine
MX2019012525A (es) 2017-04-19 2019-12-05 Glaxosmithkline Biologicals Sa Proteinas de citomegalovirus modificadas y complejos estabilizados.
SG11202002174SA (en) * 2017-09-13 2020-04-29 Sanofi Pasteur Human cytomegalovirus immunogenic composition
MX2020004434A (es) * 2017-11-01 2020-08-06 Merck Sharp & Dohme Formulaciones estables de citomegalovirus.
CN108300731A (zh) * 2018-02-02 2018-07-20 暨南大学 含有人巨细胞病毒ul115基因的重组质粒、基因工程菌及其应用
KR200492821Y1 (ko) 2018-08-10 2020-12-15 인제대학교 산학협력단 의료용 튜브 고정 기구
MX2021004273A (es) 2018-10-17 2021-12-10 Glaxosmithkline Biologicals Sa Proteinas de citomegalovirus modificadas y complejos estabilizados.
JP7179872B2 (ja) * 2018-12-10 2022-11-29 Ｋｍバイオロジクス株式会社 サイトメガロウイルスの先天性感染を予防又は治療するためのワクチン
CA3186423C (en) 2020-06-09 2024-03-19 Km Biologics Co., Ltd. Fusion protein of pentamer and gb of cytomegalovirus, and vaccine containing said fusion protein
US11406703B2 (en) 2020-08-25 2022-08-09 Modernatx, Inc. Human cytomegalovirus vaccine
KR102259156B1 (ko) 2020-09-28 2021-06-01 박나은 네트워크 환경 내 디바이스 인증 시스템 및 방법
MX2023005018A (es) 2020-10-28 2023-05-16 Sanofi Pasteur Liposomas que contienen un agonista de tlr4, preparacion y usos de los mismos.
US20250325656A1 (en) 2022-05-20 2025-10-23 Glaxosmithkline Biologicals Sa Modified varicella zoster virus glycoprotein e proteins
CN117257925B (zh) * 2023-09-20 2024-05-28 青岛大学 基于人巨细胞病毒编码即刻早期蛋白ie的疫苗、其制备方法和应用

Family Cites Families (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5244805A (en) * 1989-05-17 1993-09-14 University Of Georgia Research Foundation, Inc. Baculovirus expression vectors
AU783246C (en) * 1999-12-14 2007-03-15 Asahi Kasei Kabushiki Kaisha Stabilizing diluent for polypeptides and antigens
US7629160B2 (en) 2004-12-21 2009-12-08 University Of Kentucky Research Foundation Vectors and methods for enhanced cell longevity and protein expression
EP1783228A1 (en) 2005-11-08 2007-05-09 ETH Zürich Recombinant expression of multiprotein complexes using polygenes
WO2007146024A2 (en) * 2006-06-07 2007-12-21 The Trustees Of Princeton University Cytomegalovirus surface protein complex for use in vaccines and as a drug target
WO2012034025A2 (en) * 2010-09-09 2012-03-15 Virginia Commonwealth University Human cytomegalovirus vaccine
EP4098324A1 (en) * 2010-10-11 2022-12-07 GlaxoSmithKline Biologicals S.A. Antigen delivery platforms
CA2826199A1 (en) * 2011-01-31 2012-08-09 The Trustees Of The University Of Pennsylvania Nucleic acid molecules encoding novel herpes antigens, vaccine comprising the same, and methods of use thereof
WO2013006842A2 (en) * 2011-07-06 2013-01-10 Novartis Ag Immunogenic compositions and uses thereof
IN2014KN02929A (es) * 2012-07-06 2015-05-08 Novartis Ag
CA2885145A1 (en) * 2012-10-30 2014-05-08 Redvax Gmbh Recombinant particle based vaccines against human cytomegalovirus infection

Also Published As

Publication number Publication date
IL248803A0 (en) 2017-01-31
PH12016502220A1 (en) 2017-01-09
RU2016147987A (ru) 2018-06-13
CN106460010A (zh) 2017-02-22
TW201609792A (zh) 2016-03-16
AU2015257330A1 (en) 2016-11-17
US20150322115A1 (en) 2015-11-12
CA2947938A1 (en) 2015-11-12
EP3139953A1 (en) 2017-03-15
WO2015170287A1 (en) 2015-11-12
JP2017515503A (ja) 2017-06-15
KR20170002560A (ko) 2017-01-06
SG11201608977UA (en) 2016-11-29
MX2016014660A (es) 2017-02-28
BR112016025792A2 (pt) 2017-10-17

Similar Documents

Publication Publication Date Title
PE20170301A1 (es) Medios y metodos para el tratamiento cmv
EA201600305A1 (ru) Вариант белка opc2 pcv2 и содержащие его вирусоподобные частицы
PH12018500855A1 (en) Herpes simplex virus vaccine
CL2018000432A1 (es) Vacunas terapéuticas contra el hpv18
CL2015002709A1 (es) Inhibidores macrocíclicos de las interacciones proteína/proteína pd-1/pd-l1 y cd80(b7-1)/pd-l1
EA201890493A1 (ru) РЕПРЕССОРЫ Htt И ИХ ПРИМЕНЕНИЕ
CO2018012513A2 (es) Anticuerpos
CL2016003191A1 (es) Polipéptidos receptores formulados y métodos relacionados
MX2016013767A (es) Anticuerpos humanizados contra cd269 (bcma).
MX2018002315A (es) Anticuerpos anti muerte programada 1 (pd 1) y metodos de uso de los mismos.
CL2016002269A1 (es) Moduladores alostéricos del núcleo proteico de la hepatitis b.
EA201692098A1 (ru) Биокерамические композиции и их применение для биомодулирования
EA201790069A1 (ru) Дифторметилникотиновые инданилкарбоксамиды
PE20170665A1 (es) Anticuerpos anti-tau humanizados
EA201790630A1 (ru) Способы получения рибозидов
BR112016029178A2 (pt) composições e métodos para a expressão de rnas guia de crispr usando o promotor h1
BR112017017886A2 (pt) gerando populações de células endoteliais arteriais
MX378747B (es) Complejos de proteínas de citomegalovirus.
UY33917A (es) ?composiciones para recubrimiento que comprenden submicropartículas que comprenden carbonato de calcio, proceso para prepararlas, y uso de las submicropartículas?.
AR086871A1 (es) Composicion descongelante, proceso de preparacion, conjunto de partes y uso
EP3224712A4 (en) Support for application transparent, high available gpu computing with vm checkpointing
MX381290B (es) Formulaciones de peróxido y métodos y aplicaciones para utilizarlas.
AR086872A1 (es) Composicion descongelante, proceso de preparacion, conjunto de partes y uso
EA201790461A1 (ru) Композиции внеклеточного матрикса
MX381278B (es) Composición para la estimulación ovárica controlada.

Legal Events

Date Code Title Description
FD Application declared void or lapsed